Skip to main content
Fig. 6 | Acta Neuropathologica Communications

Fig. 6

From: Systemic delivery of a specific antibody targeting the pathological N-terminal truncated tau peptide reduces retinal degeneration in a mouse model of Alzheimer’s Disease

Fig. 6

Targeting of tau truncation by i.v. 12A12mAb injection protects against the alterations in expression level of mitochondrial proteins occurring in the retinas from Tg2576 AD mice. a, b Equal amounts of total protein extract (50 µg) from retinas of animals of three experimental groups (wild-type, Tg2576 and Tg2576 + mAb) were analyzed by SDS-PAGE with specific antibodies against several mitochondrial markers, including the Optic Atrophy Type 1 (OPA1), the outer membrane translocase 20 (TOMM 20), the Voltage-Dependent Anion-selective Channel 1/porin (VDAC 1), the Manganese SuperOxide Dismutase (MnSOD) and the Cytochrome c (Cyt c). Data were quantified for molecular weight size ranges for each antibody and normalized to β-actin which was used as loading control. Relative intensity of each protein was calculated and semi-quantitative densitometric analysis (n = 6) is shown (b). Arrows on the right side indicate the molecular weight (kDa) of bands calculated from migration of standard proteins. Statistically significant differences were calculated by one-way analysis of variance (ANOVA) followed by Bonferroni’s post-hoc test for multiple comparison among more than two groups. p < 0.05 was accepted as statistically significant (*p < 0.05; **p < 0.01; ***p < 0.0005; ****p < 0.0001)

Back to article page